Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats.
Basic fibroblast growth factor (bFGF) stimulates angiogenesis and induces neural cell regeneration. We investigated the effects of bFGF on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetic rats were treated with human recombinant bFGF as follows: 1) intravenous administration, 2) intramuscular injection into thigh and soleus muscles with cross-linked gelatin hydrogel (CGH), and 3) intramuscular injection with saline. Ten or 30 days later, the motor nerve conduction velocity (MNCV) of the sciatic-tibial and caudal nerves, sensitivity to mechanical stimuli, sciatic nerve blood flow (SNBF), and retinal blood flow (RBF) were measured. Delayed MNCV in the sciatic-tibial and caudal nerves, hypoalgesia, and reduced SNBF in diabetic rats were all ameliorated by intravenous administration of bFGF after 10, but not 30, days. Intramuscular injection of bFGF with CGH also improved sciatic-tibial MNCV, hypoalgesia, and SNBF after 10 and 30 days, but caudal MNCV was not improved. However, intramuscular injection of bFGF with saline had no significant effects. bFGF did not significantly alter RBF in either normal or diabetic rats. These observations suggest that bFGF could have therapeutic value for diabetic neuropathy and that CGH could play important roles as a carrier of bFGF.
Nakae
Mika
M
Division of Metabolic Diseases, Department of Internal Medicine, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan.
Kamiya
Hideki
H
Naruse
Keiko
K
Horio
Naoichi
N
Ito
Yasuki
Y
Mizubayashi
Ryuichi
R
Hamada
Yoji
Y
Nakashima
Eitaro
E
Akiyama
Noboru
N
Kobayashi
Yasuko
Y
Watarai
Atsuko
A
Kimura
Nachi
N
Horiguchi
Masayuki
M
Tabata
Yasuhiko
Y
Oiso
Yutaka
Y
Nakamura
Jiro
J
D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects; D003432:Cross-Linking Reagents; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D003929:Diabetic Neuropathies / Q000517:prevention & control*; D004338:Drug Combinations; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000627:therapeutic use*; D005780:Gelatin / Q000008:administration & dosage; D007273:Injections, Intramuscular; D008297:Male; D009431:Neural Conduction / Q000187:drug effects; D011099:Polyglutamic Acid / Q000008:administration & dosage; D051381:Rats; D017208:Rats, Wistar; D012171:Retinal Vessels / Q000187:drug effects / Q000503:physiopathology
D043925:Angiogenesis Inducing Agents; D003432:Cross-Linking Reagents; D004338:Drug Combinations; C101913:gelatin-polyglutamic acid glue; D016222:Fibroblast Growth Factor 2; D011099:Polyglutamic Acid; D005780:Gelatin